PPARpan agonist.7 The original synthesis of 1 (Scheme 1), not
designed for atom efficiency or waste minimization, involved
14 linear steps and was not amenable for large-scale preparation
due to many safety and scalability issues within the synthesis.7
To provide sufficient quantities of 1 for preclinical and clinical
studies, an efficient, practical, and scalable route was required.
As shown in the retrosynthetic analysis depicted in Scheme 2,
we envisioned that a regioselective carbon-sulfur bond forma-
tion could be achieved directly from the diol 3 and the
thiophenol 2 under acidic conditions.8 We predicted that a stable
carbocation would be generated preferably at the C-5 hy-
droxymethyl of the thiazole ring in diol 3.9 Thus, an SN1
displacement should be more favored at the C-5 hydroxymethyl
group,10 leading to a very efficient synthesis of 1.
An Efficient Synthesis of a Potent PPARpan
Agonist
Jiasheng Guo,* Greg A. Erickson, Russ N. Fitzgerald,
Richard T. Matsuoka, Stephen W. Rafferty,†
Matthew J. Sharp, Barry R. Sickles, and James C. Wisowaty
Synthetic Chemistry, Chemical DeVelopment, GlaxoSmithKline,
Research Triangle Park, North Carolina 27709
ReceiVed June 22, 2006
In this paper, we report an efficient and practical synthesis
of 1 in 7 steps with 30% overall yield.
The synthesis of 1 began with condensation of commercially
available diethyl 2-chloro-3-oxosuccinate (4) with 4-(trifluo-
romethyl)thiobenzamide (5) in ethanol, which afforded the
diester 6 in 83% yield (Scheme 3).
Reduction of 6 with LAH yielded diol 3. To avoid undesired
mono- and bisdesfluoro byproducts (7 and 8), which carried
through to 1 as major impurities, the reaction temperature was
maintained below -10 °C. Thus the reduction was carried out
at -10 to -15 °C in THF followed by acid workup with
aqueous sulfuric acid, affording 3 in 83% yield without the
formation of the desfluoro side products.
We next turned our attention to the regioselective carbon-
sulfur bond formation at the C-5 hydroxymethyl. We explored
two approaches to form the carbon-sulfur bond: synthesis of
the thiophenol 2 and in situ coupling with 3; direct coupling of
3 with commercially available 4-hydroxythiophenol. To pursue
An efficient synthesis of 2-{4-[({4-{[4-(4-methoxyphenyl)-
piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-
thiazol-5-yl}methyl)thio]phenoxy}-2-methylpropanoic acid
(1), a potent PPARpan agonist, is described. The seven-step
synthesis, which afforded 1 in 30% overall yield, includes a
highly regioselective carbon-sulfur bond formation via
coupling of a bishydroxymethylthiazole (3) with 4-hydrox-
ythiophenol, displacement of the remaining alcohol through
a three-step telescoped sequence involving an efficient
cleavage of an aryl mesylate, and an efficient and practical
method of introducing an isobutyric acid fragment.
(7) Banker, P.; Cadilla, R.; Lambert, M. H., III; Rafferty, S. W.;
Sternbach, D. D.; Sznaidman, M. L. PCT Int. Appl. WO2002059098.
(8) For examples of acid-promoted displacement of activated alcohols,
such as benzylic alcohols, by thiols, see: (a) Micha-Screttas, M.; Screttas,
C. G. J. Org. Chem. 1977, 42, 1462. (b) Guindon, Y.; Frenette, R.; Fortin,
R.; Rokach, J. J. Org. Chem. 1983, 48, 1357. (c) Manabe, K.; Limura, S.;
Sun, X.-M.; Kobayashi, S. J. Am. Chem. Soc. 2002, 124, 11971. (d)
Breitschuh, R.; Seebach, D. Synthesis 1992, 83. (e) Stewart, A. S. J.; Drey,
C. N. C. J. Chem. Soc., Perkin Trans. 1 1990, 1753. (f) Bouwman, E.;
Driessen, W. L. Synth. Commun. 1988, 18, 1581.
(9) Under acidic conditions, 3 may form carbocations at two positions,
C-5 hydroxymethyl carbon (carbocation A) or C-4 hydroxymethyl carbon
(carbocation B). The carbocation A has greater stability because of the
increased delocalization due to resonance (7 canonical forms) within the
thiazole and the benzene rings, while the carbocation B (3 canonical forms)
is stabilized only by delocalization with a 4,5-double bond and the mercapto
atom.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-sensitive nuclear factors with three subtypes: PPARR,
PPARγ, and PPARδ. PPARs play an important role in many
cellular functions and have emerged as therapeutic targets for
the treatment of human metabolic diseases.1-6 To address
multiple metabolic disorders more effectively, the simultaneous
activation of PPARR, PPARγ, and PPARδ by a single com-
pound (i.e., a PPARpan agonist) is being pursued. Furthermore,
the simultaneous activation of individual PPARs with a single
pan molecule may result in synergistic effects, affording
enhanced biological activity and increased potency.6 On the basis
of preclinical data, compound 1 was identified as a potent
† Department of Medicinal Chemistry.
(1) Wilson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. J. Med.
Chem. 2000, 43, 527.
(2) Sternbach, D. D. Ann. Rep. Med. Chem. 2003, 38, 71.
(3) Kersten, S.; Desvergne, B.; Wahli, W. Nature 2000, 405, 421.
(4) Berger, J.; Moller, D. E. Annu. ReV. Med. 2002, 53, 409.
(5) Evans, R. M.; Barish, G. D.; Wang, Y.-X. Nat. Med. 2004, 10, 1.
(6) Evans, J. L.; Lin, J. J.; Goldfine, I. D. Curr. Diabetes ReV. 2005, 1,
299.
(10) On the basis of MOPAC/PM3 calculations, it was found that the
carbocation A is 11 kcal/mol lower in energy than that of the carbocation
B. This result indicates that the primary product should be the expected
one.
10.1021/jo061295n CCC: $33.50 © 2006 American Chemical Society
Published on Web 09/12/2006
8302
J. Org. Chem. 2006, 71, 8302-8305